AVIR Earnings Date: Nov 11, 2026 (Estimated) — Atea Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is AVIR's next earnings date?
Atea Pharmaceuticals, Inc. (AVIR) is expected to report Q3 2026 earnings on Wednesday, November 11, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.51 on revenue of $50.4M.
How did AVIR do in its last earnings report?
In its most recent report on Aug 12, 2026 (Q2 2026), Atea Pharmaceuticals, Inc. posted EPS of -$0.41 versus the -$0.56 estimate, a beat of 26.8%. Revenue was $0 against a $33.0M estimate. The stock's 1-day post-earnings move was +0.2%.
How much does AVIR stock move after earnings?
AVIR beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.5% (up or down) in the day after earnings.
About Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | -0.56 | -0.41 | +26.79% | $0 | ✅ Beat | +0.20% | +10.47% | +4.94% |
| 2026-05-12 | Q1 2026 | -0.56 | -0.57 | -1.79% | $0 | ❌ Miss | -16.91% | -24.55% | -20.73% |
| 2026-03-05 | Q4 2025 | -0.48 | -0.57 | -18.75% | $0 | ❌ Miss | +11.13% | +15.09% | +10.75% |
| 2025-11-12 | Q3 2025 | -0.43 | -0.53 | -23.26% | $0 | ❌ Miss | -12.57% | -10.00% | -10.00% |
| 2025-08-07 | Q2 2025 | -0.43 | -0.44 | -2.33% | $0 | ❌ Miss | -2.31% | +0.87% | -6.07% |
| 2025-03-06 | Q4 2024 | -0.29 | -0.40 | -37.93% | $0 | ❌ Miss | -0.33% | +2.00% | -7.00% |
| 2024-11-07 | Q3 2024 | -0.49 | -0.37 | +24.49% | $0 | ✅ Beat | +1.74% | -3.78% | -12.21% |
| 2024-08-07 | Q2 2024 | -0.76 | -0.48 | +36.84% | $0 | ✅ Beat | +7.03% | +10.09% | +10.09% |
Showing last 8 quarters.